fludarabine has been researched along with Infections, Respiratory in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busch, R; Eichhorst, BF; Emmerich, B; Hallek, M; Schweighofer, C; Wendtner, CM | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Martell, RE; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
2 trial(s) available for fludarabine and Infections, Respiratory
| Article | Year |
|---|---|
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Multivariate Analysis; Remission Induction; Respiratory Tract Infections; Risk Factors; Survival Rate; Vidarabine | 2007 |
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Ontario; Respiratory Tract Infections; Skin Diseases, Infectious; Treatment Outcome; United States; Vidarabine | 2001 |